Animal trials proved efficacy of Covaxin, India’s Covid-19 vaccine candidate, says Bharat Biotech  | The Business Standard
Skip to main content
  • Epaper
  • Economy
    • Aviation
    • Banking
    • Bazaar
    • Budget
    • Industry
    • NBR
    • RMG
    • Corporates
  • Stocks
  • Analysis
  • Videos
    • TBS Today
    • TBS Stories
    • TBS World
    • News of the day
    • TBS Programs
    • Podcast
    • Editor's Pick
  • World+Biz
  • Features
    • Panorama
    • The Big Picture
    • Pursuit
    • Habitat
    • Thoughts
    • Splash
    • Mode
    • Tech
    • Explorer
    • Brands
    • In Focus
    • Book Review
    • Earth
    • Food
    • Luxury
    • Wheels
  • Subscribe
    • Epaper
    • GOVT. Ad
  • More
    • Sports
    • TBS Graduates
    • Bangladesh
    • Supplement
    • Infograph
    • Archive
    • Gallery
    • Long Read
    • Interviews
    • Offbeat
    • Magazine
    • Climate Change
    • Health
    • Cartoons
  • বাংলা
The Business Standard

Wednesday
May 28, 2025

Sign In
Subscribe
  • Epaper
  • Economy
    • Aviation
    • Banking
    • Bazaar
    • Budget
    • Industry
    • NBR
    • RMG
    • Corporates
  • Stocks
  • Analysis
  • Videos
    • TBS Today
    • TBS Stories
    • TBS World
    • News of the day
    • TBS Programs
    • Podcast
    • Editor's Pick
  • World+Biz
  • Features
    • Panorama
    • The Big Picture
    • Pursuit
    • Habitat
    • Thoughts
    • Splash
    • Mode
    • Tech
    • Explorer
    • Brands
    • In Focus
    • Book Review
    • Earth
    • Food
    • Luxury
    • Wheels
  • Subscribe
    • Epaper
    • GOVT. Ad
  • More
    • Sports
    • TBS Graduates
    • Bangladesh
    • Supplement
    • Infograph
    • Archive
    • Gallery
    • Long Read
    • Interviews
    • Offbeat
    • Magazine
    • Climate Change
    • Health
    • Cartoons
  • বাংলা
WEDNESDAY, MAY 28, 2025
Animal trials proved efficacy of Covaxin, India’s Covid-19 vaccine candidate, says Bharat Biotech 

Coronavirus chronicle

Hindustan Times
12 September, 2020, 01:10 pm
Last modified: 12 September, 2020, 04:21 pm

Related News

  • 3D-printed device could end animal trials for pharmaceuticals
  • India launches world’s 1st intranasal Covid vaccine
  • ‘Big boost’: Bharat Biotech’s nasal Covid-19 vaccine gets green light
  • Pfizer says 3 Covid shots protect children under 5
  • Covax calls for urgent action to close vaccine equity gap

Animal trials proved efficacy of Covaxin, India’s Covid-19 vaccine candidate, says Bharat Biotech 

Animal trials proved efficacy of Covaxin, India’s Covid-19 vaccine candidate, says Bharat Biotech 

Hindustan Times
12 September, 2020, 01:10 pm
Last modified: 12 September, 2020, 04:21 pm
A man rides his motorbike past a parked bus of India's biotechnology company Bharat Biotech outside its office in Hyderabad, India July 3, 2020. REUTERS/Stringer
A man rides his motorbike past a parked bus of India's biotechnology company Bharat Biotech outside its office in Hyderabad, India July 3, 2020. REUTERS/Stringer

Animal trials of Bharat Biotech International Limited's Covid-19 vaccine candidate, Covaxin, have been successful and the results showed the shot's "remarkable immunogenicity and protective efficacy" in the Phase I clinical trials in India, the drugmaker has said.

Covaxin, developed by the Indian Council of Medical Research (ICMR) and Bharat Biotech, is being tested at 12 institutes across India. The Hyderabad-based firm said the data from the study on primates substantiate the immunogenicity of the vaccine candidate.

"Bharat Biotech proudly announces the animal study results of COVAXIN - These results demonstrate the protective efficacy in a live viral challenge model," Bharat Biotech tweeted on Friday.

The Business Standard Google News Keep updated, follow The Business Standard's Google news channel

Bharat Biotech has said in a release that it developed and assessed the protective efficacy and immunogenicity of an inactivated Sar-CoV-2 vaccine (BBV152) or Covaxin in rhesus macaques. Twenty macaques were divided into four groups of five animals each, it said.

India initiates first human trials of coronavirus vaccine

"One group was administered a placebo while three groups were immunised with three different vaccine candidates at 0 and 14 days. All the macaques were challenged with SARS-CoV-2 14 days after the second dose. The protective response was observed with increasing SARS-CoV-2 specific IgG and neutralising antibody titres from third week post-immunisation," the drug company said.

It added that viral clearance was observed from "bronchoalveolar lavage fluid, nasal swab, throat swab, and lung tissues at 7 days post-infection in the vaccinated groups."

"No evidence of pneumonia was observed by histopathological examination in vaccinated groups, unlike the placebo group which showed features of interstitial pneumonia and localisation of viral antigen in the alveolar epithelium and macrophages by immunohistochemistry," it added.

"To summarize, the vaccine candidate was found to generate robust immune responses. Thus, preventing infection and disease in the primates upon high amounts of exposure to live SARS-CoV-2 virus," it added.

Bharat Biotech had received approval from the Central Drugs Standard Control Organisation to conduct the Phase-II trials earlier this month. It had announced in June that it successfully developed Covaxin in collaboration with ICMR and the National Institute of Virology (NIV).

The SARS-CoV-2 strain was isolated in NIV, Pune and transferred to Bharat Biotech. The indigenous, inactivated vaccine candidate has been developed and manufactured in Bharat Biotech's high containment facility located in Genome Valley, Hyderabad.

Covaxin is one of the frontrunners in the race for a Covid-19 vaccine in India. It is an "inactivated" vaccine — it works by injecting doses of the virus that have been killed aiming to prompt the body to build antibodies against it without the virus posing a threat.

Each stage of a vaccine's clinical trial tests its safety and ability to develop an effective immune response. Phase 1 focuses on determining safety and dosage in a small group of healthy participants, while Phase 2 looks at the vaccine's effectiveness. Phase 3 looks into these aspects in a much larger population that would represent a wider demographic.

Top News

Bharat Biotech / Coronavirus Vaccine / animal trial / COVAXIN

Comments

While most comments will be posted if they are on-topic and not abusive, moderation decisions are subjective. Published comments are readers’ own views and The Business Standard does not endorse any of the readers’ comments.

Top Stories

  • How termination of USDA-funded trade facilitation project will affect Bangladesh
    How termination of USDA-funded trade facilitation project will affect Bangladesh
  • File photo of Bangladesh Secretariat. Photo: Collected
    Visitors banned from entering Secretariat on Mondays and Thursdays
  • File photo of BNP Secretary General Mirza Fakhrul Islam Alamgir. Photo: Collected
    Asked for roadmap, govt didn’t give in 10 months, now 'December it is': Mirza Fakhrul

MOST VIEWED

  • Google Pay. Photo: Collected
    Google Pay likely coming to Bangladesh soon
  • Graphics: TBS
    Suspicious banking activities surge by 56% since July: Cenbank
  • Representational image of cable car/Freepik
    Cable car to be installed from Himchari to Reju Khal in Marine Drive Road
  • Illustration: TBS
    Bangladesh sees highest-ever per capita income of $2,820 in FY25, BBS provisional data shows
  • IFIC Bank receives Tk6,000 cr in new deposits in six months
    IFIC Bank receives Tk6,000 cr in new deposits in six months
  • Abdul Awal Mintoo, chairman of National Bank Limited. Sketch: TBS
    'Regulatory support must for National Bank to restore depositors' confidence'

Related News

  • 3D-printed device could end animal trials for pharmaceuticals
  • India launches world’s 1st intranasal Covid vaccine
  • ‘Big boost’: Bharat Biotech’s nasal Covid-19 vaccine gets green light
  • Pfizer says 3 Covid shots protect children under 5
  • Covax calls for urgent action to close vaccine equity gap

Features

In recent years, the Gor-e-Shaheed Eidgah has emerged as a strong contender for the crown of the biggest Eid congregation in the country, having hosted 600,000 worshippers in 2017. Photo: TBS

Gor-e-Shaheed Boro Maath: The heart of Dinajpur

2d | Panorama
The Hili Land Port, officially opened in 1997 but with trade roots stretching back to before Partition, has grown into a cornerstone of bilateral commerce.

Dhaka-Delhi tensions ripple across Hili’s markets and livelihoods

3d | Panorama
Photo: Collected

Desk goals: Affordable ways to elevate your study setup

3d | Brands
Built on a diamond-type frame, the Hornet 2.0 is agile but grounded. PHOTO: Asif Chowdhury

Honda Hornet 2.0: Same spirit, upgraded sting

3d | Wheels

More Videos from TBS

Trump's tariff strategy and Europe's investment politics, violence or negotiation?

Trump's tariff strategy and Europe's investment politics, violence or negotiation?

29m | Others
Rumours surrounding the Club World Cup: Which club will Ronaldo join?

Rumours surrounding the Club World Cup: Which club will Ronaldo join?

39m | Others
News of The Day, 26 MAY 2025

News of The Day, 26 MAY 2025

2h | TBS News of the day
Google Pay likely coming to Bangladesh soon

Google Pay likely coming to Bangladesh soon

3h | TBS Programs
EMAIL US
contact@tbsnews.net
FOLLOW US
WHATSAPP
+880 1847416158
The Business Standard
  • About Us
  • Contact us
  • Sitemap
  • Advertisement
  • Privacy Policy
  • Comment Policy
Copyright © 2025
The Business Standard All rights reserved
Technical Partner: RSI Lab

Contact Us

The Business Standard

Main Office -4/A, Eskaton Garden, Dhaka- 1000

Phone: +8801847 416158 - 59

Send Opinion articles to - oped.tbs@gmail.com

For advertisement- sales@tbsnews.net